Pds biotech announces 36-month overall survival rate of 84.4% in locally advanced cervical cancer patients treated with versamune® hpv and chemoradiation

100% 36-month overall survival (os) and progression-free survival (pfs) rates in patients fully  treated with versamune ® hpv combined with chemoradiation (n=8) 88% (15/17) of patients had a complete metabolic response immunocerv phase 2 clinical trial results presented at astro annual meeting 2024
PDSB Ratings Summary
PDSB Quant Ranking